CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: June 17, 2014
Result type: Reports
Project Number: SE0384-000
Product Line: Reimbursement Review

Generic Name: Infliximab

Brand Name: Inflectra

Manufacturer: Hospira Healthcare Corporation

Therapeutic Area: Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis

Indications: Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

Submission Type: Initial

Project Status: Complete

Biosimilar: Yes

Date Recommendation Issued: December 19, 2014

Recommendation Type: List with criteria/condition